BI-1701963 has potential applications in the treatment of various diseases, including adenocarcinoma, advanced solid tumors, biliary tract cancer, colorectal cancer, lung tumors, metastatic colorectal cancer, and metastatic pancreatic cancer.334 It has entered phase I clinical trials (NCT04111458) in October 2019 to explore different doses of BI-1701963 alone and in combination with trametinib, a MEK inhibitor, in patients with different types of advanced cancer (KRAS mutant solid tumor). Here, KRAS is linked to cancer.